Protect your patient’s kidneys
Rhabdomyolysis results in release of myoglobin into the bloodstream. Excessive myoglobin can accumulate in the kidneys and lead to acute kidney injury (AKI).
CytoSorb in severe rhabdomyolysis
CytoSorb® hemoadsorption goes beyond renal replacement therapies – it can help support the recovery of kidney function when conventional strategies to remove myoglobin alone prove ineffective.
Hyperinflammation caused by rhabdomyolysis can aggravate AKI and should also be addressed. Early protection of the kidneys helps improve the patient’s prognosis, and early myoglobin clearance may even help prevent AKI.
CytoSorb is a unique technology that’s proven to effectively, safely and simultaneously reduce both elevated levels of cytokines and myoglobin, thereby supporting the recovery of renal function.

CytoSorb can be used to address important challenges in severe rhabdomyolysis
Manage rhabdomyolysis
CytoSorb has been shown to effectively and safely remove elevated levels of myoglobin, while additionally addressing any concomitant hyperinflammation, helping in the management of rhabdomyolysis.

Best practice therapy management
Additional Information
- Albrecht et al., Blood Purif 2024; 53(2):88-95
- Grafe et al., Ren Fail 2023; 45(2):2259231
- Scharf et al., Crit Care 2021; 25(1):41
- Chavez et al., Crit Care 2016; 20(1):135
- Boutaud et al., Proc Natl Acad Sci USA 2010; 107(6):2699-704
- Bosch et al., N Engl J Med 2009; 361(1):62-72
- Khan et al., Neth J Med 2009; 67(9):272-283
- Chatzizisis et al., Eur J Intern Med 2008; 19(8):568-574
Voices around the world

Access Healthcare Professionals Area
This area is for Health Care Professionals only and provides reports about clinical experiences gained during the use of CytoSorbents products. The information presented reflects the opinions and procedural techniques of individual physicians and is not intended as medical advice. Physician experience, risks, patient outcomes and results may vary. This content is intended for Health Care Professionals outside the United States and Canada as CytoSorb has not yet been approved or cleared in the United States or Canada for any indication, except under an Emergency Use Authorization (EUA) by the US FDA.